UBS AM’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $12.7M | Buy |
585,671
+59,374
| +11% | +$1.29M | ﹤0.01% | 1240 |
|
|
2025
Q1 | $12.8M | Buy |
526,297
+262,392
| +99% | +$6.36M | ﹤0.01% | 1128 |
|
|
2024
Q4 | $5.51M | Buy |
263,905
+27,683
| +12% | +$578K | ﹤0.01% | 1560 |
|
|
2024
Q3 | $4.7M | Sell |
236,222
-14,898
| -6% | -$296K | ﹤0.01% | 1608 |
|
|
2024
Q2 | $3.89M | Buy |
251,120
+135,376
| +117% | +$2.1M | ﹤0.01% | 1630 |
|
|
2024
Q1 | $1.84M | Buy |
115,744
+255
| +0.2% | +$4.07K | ﹤0.01% | 1721 |
|
|
2023
Q4 | $1.94M | Hold |
115,489
| – | – | ﹤0.01% | 1707 |
|
|
2023
Q3 | $1.35M | Sell |
115,489
-21,588
| -16% | -$252K | ﹤0.01% | 1798 |
|
|
2023
Q2 | $2.27M | Hold |
137,077
| – | – | ﹤0.01% | 1582 |
|
|
2023
Q1 | $2.27M | Buy |
137,077
+10,126
| +8% | +$168K | ﹤0.01% | 1582 |
|
|
2022
Q4 | $2.36M | Buy |
126,951
+5,814
| +5% | +$108K | ﹤0.01% | 1456 |
|
|
2022
Q3 | $1.55M | Sell |
121,137
-831
| -0.7% | -$10.7K | ﹤0.01% | 1727 |
|
|
2022
Q2 | $855K | Sell |
121,968
-3,790
| -3% | -$26.6K | ﹤0.01% | 2054 |
|
|
2022
Q1 | $1.04M | Sell |
125,758
-38,900
| -24% | -$322K | ﹤0.01% | 2116 |
|
|
2021
Q4 | $1.11M | Buy |
164,658
+26,983
| +20% | +$183K | ﹤0.01% | 2156 |
|
|
2021
Q3 | $730K | Sell |
137,675
-64,800
| -32% | -$343K | ﹤0.01% | 2324 |
|
|
2021
Q2 | $1.16M | Buy |
202,475
+7,474
| +4% | +$43K | ﹤0.01% | 2130 |
|
|
2021
Q1 | $899K | Hold |
195,001
| – | – | ﹤0.01% | 2146 |
|
|
2020
Q4 | $651K | Buy |
195,001
+97,700
| +100% | +$326K | ﹤0.01% | 2194 |
|
|
2020
Q3 | $289K | Sell |
97,301
-2,852
| -3% | -$8.47K | ﹤0.01% | 2314 |
|
|
2020
Q2 | $463K | Sell |
100,153
-490
| -0.5% | -$2.26K | ﹤0.01% | 2156 |
|
|
2020
Q1 | $387K | Buy |
100,643
+6,881
| +7% | +$26.5K | ﹤0.01% | 2072 |
|
|
2019
Q4 | $352K | Sell |
93,762
-13,759
| -13% | -$51.6K | ﹤0.01% | 2334 |
|
|
2019
Q3 | $571K | Buy |
107,521
+31,148
| +41% | +$165K | ﹤0.01% | 2225 |
|
|
2019
Q2 | $293K | Buy |
+76,373
| New | +$293K | ﹤0.01% | 2423 |
|